Is overdilatation of 3.0 mm sirolimus-eluting stent associated with a higher restenosis rate?

Ioannis Iakovou, Goran Stankovic, Matteo Montorfano, Flavio Airoldi, Alaide Chieffo, Giuseppe M. Sangiorgi, Mauro Carlino, Nicola Corvaja, Michev Iassen, Renata Rogacka, Giancarlo Vitrella, Antonio Colombo

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We evaluated the safety and effectiveness of postdilating a 3.0 mm sirolimus-eluting stents (SESs; six cells) with a 3.5-4.0 mm balloon. We identified 254 consecutive patients who underwent percutaneous coronary interventions using SESs with a nominal diameter of 3.0 mm (six cells). Patients were divided into two groups based on whether they were subsequently postdilated with a 3.0 mm (group 1: 168 patients, 251 lesions) or a 3.5-4 mm balloon (group 2: 86 patients, 102 lesions). There were no significant differences regarding the incidence of in-hospital and long-term follow-up. Angiographic follow-up was available in 72% and 74% of groups 1 and 2, respectively. The two groups had no significant differences regarding late lumen loss (0.51 ± 0.36 vs. 0.52 ± 0.33; P = 0.3) and binary restenosis rates (10.7% vs. 8.8%; P = 0.1). Six-month clinical follow-up was available in all patients. At long-term follow-up (mean: 10.6 ± 3.7 for group 1 and 11.3 ± 3.9 months for group 2), there were no significant differences between the two groups regarding major adverse cardiac events (8.9% vs. 9.2%; P = 0.9). Implantation of a 3.0 mm SES with postdilation with a 3.5-4 mm balloon did not result in any significant difference in complications, in-hospital non-Q-wave myocardial infarction, binary restenosis, or target lesion revascularization. These data should lessen concern that overdilation may dilute the beneficial effects of SESs.

Original languageEnglish
Pages (from-to)129-133
Number of pages5
JournalCatheterization and Cardiovascular Interventions
Volume64
Issue number2
DOIs
Publication statusPublished - Feb 2005

Fingerprint

Sirolimus
Stents
Percutaneous Coronary Intervention
Myocardial Infarction
Safety
Incidence

Keywords

  • Drug-eluting stents
  • Overdilatation
  • Percutaneous coronary interventions

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Is overdilatation of 3.0 mm sirolimus-eluting stent associated with a higher restenosis rate? / Iakovou, Ioannis; Stankovic, Goran; Montorfano, Matteo; Airoldi, Flavio; Chieffo, Alaide; Sangiorgi, Giuseppe M.; Carlino, Mauro; Corvaja, Nicola; Iassen, Michev; Rogacka, Renata; Vitrella, Giancarlo; Colombo, Antonio.

In: Catheterization and Cardiovascular Interventions, Vol. 64, No. 2, 02.2005, p. 129-133.

Research output: Contribution to journalArticle

Iakovou, Ioannis ; Stankovic, Goran ; Montorfano, Matteo ; Airoldi, Flavio ; Chieffo, Alaide ; Sangiorgi, Giuseppe M. ; Carlino, Mauro ; Corvaja, Nicola ; Iassen, Michev ; Rogacka, Renata ; Vitrella, Giancarlo ; Colombo, Antonio. / Is overdilatation of 3.0 mm sirolimus-eluting stent associated with a higher restenosis rate?. In: Catheterization and Cardiovascular Interventions. 2005 ; Vol. 64, No. 2. pp. 129-133.
@article{d680a73f253f4da7925d583a3f97b7a6,
title = "Is overdilatation of 3.0 mm sirolimus-eluting stent associated with a higher restenosis rate?",
abstract = "We evaluated the safety and effectiveness of postdilating a 3.0 mm sirolimus-eluting stents (SESs; six cells) with a 3.5-4.0 mm balloon. We identified 254 consecutive patients who underwent percutaneous coronary interventions using SESs with a nominal diameter of 3.0 mm (six cells). Patients were divided into two groups based on whether they were subsequently postdilated with a 3.0 mm (group 1: 168 patients, 251 lesions) or a 3.5-4 mm balloon (group 2: 86 patients, 102 lesions). There were no significant differences regarding the incidence of in-hospital and long-term follow-up. Angiographic follow-up was available in 72{\%} and 74{\%} of groups 1 and 2, respectively. The two groups had no significant differences regarding late lumen loss (0.51 ± 0.36 vs. 0.52 ± 0.33; P = 0.3) and binary restenosis rates (10.7{\%} vs. 8.8{\%}; P = 0.1). Six-month clinical follow-up was available in all patients. At long-term follow-up (mean: 10.6 ± 3.7 for group 1 and 11.3 ± 3.9 months for group 2), there were no significant differences between the two groups regarding major adverse cardiac events (8.9{\%} vs. 9.2{\%}; P = 0.9). Implantation of a 3.0 mm SES with postdilation with a 3.5-4 mm balloon did not result in any significant difference in complications, in-hospital non-Q-wave myocardial infarction, binary restenosis, or target lesion revascularization. These data should lessen concern that overdilation may dilute the beneficial effects of SESs.",
keywords = "Drug-eluting stents, Overdilatation, Percutaneous coronary interventions",
author = "Ioannis Iakovou and Goran Stankovic and Matteo Montorfano and Flavio Airoldi and Alaide Chieffo and Sangiorgi, {Giuseppe M.} and Mauro Carlino and Nicola Corvaja and Michev Iassen and Renata Rogacka and Giancarlo Vitrella and Antonio Colombo",
year = "2005",
month = "2",
doi = "10.1002/ccd.20276",
language = "English",
volume = "64",
pages = "129--133",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Is overdilatation of 3.0 mm sirolimus-eluting stent associated with a higher restenosis rate?

AU - Iakovou, Ioannis

AU - Stankovic, Goran

AU - Montorfano, Matteo

AU - Airoldi, Flavio

AU - Chieffo, Alaide

AU - Sangiorgi, Giuseppe M.

AU - Carlino, Mauro

AU - Corvaja, Nicola

AU - Iassen, Michev

AU - Rogacka, Renata

AU - Vitrella, Giancarlo

AU - Colombo, Antonio

PY - 2005/2

Y1 - 2005/2

N2 - We evaluated the safety and effectiveness of postdilating a 3.0 mm sirolimus-eluting stents (SESs; six cells) with a 3.5-4.0 mm balloon. We identified 254 consecutive patients who underwent percutaneous coronary interventions using SESs with a nominal diameter of 3.0 mm (six cells). Patients were divided into two groups based on whether they were subsequently postdilated with a 3.0 mm (group 1: 168 patients, 251 lesions) or a 3.5-4 mm balloon (group 2: 86 patients, 102 lesions). There were no significant differences regarding the incidence of in-hospital and long-term follow-up. Angiographic follow-up was available in 72% and 74% of groups 1 and 2, respectively. The two groups had no significant differences regarding late lumen loss (0.51 ± 0.36 vs. 0.52 ± 0.33; P = 0.3) and binary restenosis rates (10.7% vs. 8.8%; P = 0.1). Six-month clinical follow-up was available in all patients. At long-term follow-up (mean: 10.6 ± 3.7 for group 1 and 11.3 ± 3.9 months for group 2), there were no significant differences between the two groups regarding major adverse cardiac events (8.9% vs. 9.2%; P = 0.9). Implantation of a 3.0 mm SES with postdilation with a 3.5-4 mm balloon did not result in any significant difference in complications, in-hospital non-Q-wave myocardial infarction, binary restenosis, or target lesion revascularization. These data should lessen concern that overdilation may dilute the beneficial effects of SESs.

AB - We evaluated the safety and effectiveness of postdilating a 3.0 mm sirolimus-eluting stents (SESs; six cells) with a 3.5-4.0 mm balloon. We identified 254 consecutive patients who underwent percutaneous coronary interventions using SESs with a nominal diameter of 3.0 mm (six cells). Patients were divided into two groups based on whether they were subsequently postdilated with a 3.0 mm (group 1: 168 patients, 251 lesions) or a 3.5-4 mm balloon (group 2: 86 patients, 102 lesions). There were no significant differences regarding the incidence of in-hospital and long-term follow-up. Angiographic follow-up was available in 72% and 74% of groups 1 and 2, respectively. The two groups had no significant differences regarding late lumen loss (0.51 ± 0.36 vs. 0.52 ± 0.33; P = 0.3) and binary restenosis rates (10.7% vs. 8.8%; P = 0.1). Six-month clinical follow-up was available in all patients. At long-term follow-up (mean: 10.6 ± 3.7 for group 1 and 11.3 ± 3.9 months for group 2), there were no significant differences between the two groups regarding major adverse cardiac events (8.9% vs. 9.2%; P = 0.9). Implantation of a 3.0 mm SES with postdilation with a 3.5-4 mm balloon did not result in any significant difference in complications, in-hospital non-Q-wave myocardial infarction, binary restenosis, or target lesion revascularization. These data should lessen concern that overdilation may dilute the beneficial effects of SESs.

KW - Drug-eluting stents

KW - Overdilatation

KW - Percutaneous coronary interventions

UR - http://www.scopus.com/inward/record.url?scp=19944431246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944431246&partnerID=8YFLogxK

U2 - 10.1002/ccd.20276

DO - 10.1002/ccd.20276

M3 - Article

VL - 64

SP - 129

EP - 133

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 2

ER -